Sartorius AG

RSS Feed
Sartorius is a holding company, which is engaged as an international laboratory and process technology provider for the biotech, pharmaceutical and food industries. Co. has three segments: the Bioprocess Solutions, which provides solutions for the core process steps in biopharmaceutical production, focusing on the areas of activity of filtration, fluid management, fermentation, and purification; the Lab Products & Services, which serves both research and quality assurance laboratories across several different industries; and the Industrial Weighing, which concentrates on weighing and control applications in the manufacturing processes of the food, chemical and pharmaceutical sectors.
  • TickerSRT
  • ISINDE0007165607
  • SectorHealth Care Equipment & Services
  • CountryGermany
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.22
Equity
Technology
ACCD , ACD ...
58d 23/11/2020 28 EN
EQUITS GmbH
Thomas J. Schiessle

Vorbereitungen für COVID-19-Vaccine bringt Orderschub von 60 % in Q3/20 - 4. Guidance-Anpassung für Gj. 2020

Überraschend kräftig entwickelte sich Q3/20; BPS (+26 % auf € 144,5 Mio.) wuchs anhaltend zweistellig; LPS (+44,1 % auf € 478,7 Mio.) beendete (mit Wiedereröffnung der akademischen Labore) die Schwächephase des H1/20 in allen Regionen. Der Ordereingang erreichte € 711,7 Mio. (+54,5% ggü. Vj; in CC: +60% - davon ca. 30%-Punkte COVID-19-bedingt). Der Q3/20-Konzern­umsatz stieg um +39,5 % ggü. Vj. (EMEA: +37,4%; Amerika: +38,7 %; Asia/Pacific:  +27,3 %) auf € 623,2 Mio. So gesehen könnte die herrschende Konzern-Mittelfristperspektive angehoben werden, sofern die anlaufende 2. Corona-Welle nicht ...

EUR 220.00
Equity
Health Care
SRT , SRT3 ...
92d 21/10/2020 4 DE
EQUITS GmbH
Thomas J. Schiessle

Preparations for COVID-19 vaccine brings order surge of 60 % in Q3/20 - 4th guidance adjustment for FY 2020

  Q3/20 developed surprisingly strongly; BPS (+26 % to € 144.5 m) continued to grow at double-digit rates; LPS (+44.1 % to € 478.7 m) ended the weak phase of H1/20 (with the reopening of academic laboratories) in all regions. Order intake reached € 711.7 m (+54.5 % vs. previous year; in CC: +60 % - thereof approx. 30 % points COVID-19 related). Consolidated sales in Q3/20 rose by +39.5 % year-on-year (EMEA: +37.4 %; America: +38.7 %; Asia/Pacific: +27.3 %) to € 623.2 m. Seen in this light, the prevailing medium-term outlook for the Group could be raised, provided that the ongoing second wave...

EUR 220.00
Equity
Health Care
SRT , SRT3 ...
92d 21/10/2020 4 EN
EQUITS GmbH
Thomas J. Schiessle

BIA Seperations Kauf verbessert Perspektiven

Für € 360 Mio. - davon für € 120 Mio. in Stedim Aktien – (+ Earn-out) wird der Aufreinigungsspezialist BIA Seperations (ca. 120 Mitarbeiter, Jahresumsatz: ca. € 25 Mio.) gekauft. Strategisch bedeutend: Das BIA-Produktportfolio ist im Markt anerkannt und erschließt künftige Medikamentenklassen (Advanced Therapies) für den global agierenden SRT-Konzern.

EUR 220.00
Equity
Health Care
SRT , 56S1
107d 06/10/2020 4 DE
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

EM Pullback Opportunity Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point, concerns surrounding the Wuhan coronavirus have led to some market setbacks and deterioration in market indicators, however they have not resulted in breakdowns. This is true even for areas of the market most-directly affected, including China (MSCI China) and emerging markets (MSCI EM). For these reasons and, as long as there is no significant additional damage, we view recent weakness as a buying opportunity - especially ...

EUR 206.10
Chart
Health Care
AMP , ARCAD ...
1y 27/01/2020 18 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

EM Pullback Opportunity Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point, concerns surrounding the Wuhan coronavirus have led to some market setbacks and deterioration in market indicators, however they have not resulted in breakdowns. This is true even for areas of the market most-directly affected, including China (MSCI China) and emerging markets (MSCI EM). For these reasons and, as long as there is no significant additional damage, we view recent weakness as a buying opportunity - especially ...

EUR 206.10
Chart
Health Care
AMP , ARCAD ...
1y 27/01/2020 18 EN
BusinessWire

Sartorius Acquires a Majority Stake in Cell Culture Media Specialist Biological Industries

GÖTTINGEN, Germany--(BUSINESS WIRE)-- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, signed an agreement to acquire a majority stake in the Israeli cell culture media developer and manufacturer Biological Industries. For approximately €45 million in cash, Sartorius is acquiring just over 50% of the shares of the company from its owners, Kibbutz Beit Haemek and private equity fund Fortissimo Capital. An option to acquire a further 20% of the shares within three years was also agreed. The transaction is subject to customary closing condit...

Free
Corporate Voice
Health Care
Sartorius AG
1y 05/12/2019 1 EN
BusinessWire

Sartorius Signs Agreement to Acquire Select Danaher Life Science Platform Businesses

GÖTTINGEN, Germany--(BUSINESS WIRE)-- Sartorius, a leading partner to the biopharmaceutical industry and laboratories, has signed an agreement to acquire parts of Danaher’s Life Science portfolio for approximately $750 million in cash. The businesses had combined sales turnover of approximately $140 million in 2018 with a strong growth profile and double-digit profit margins. They employ around 300 people worldwide. The proposed transaction is expected to be completed in the first quarter of 2020 and is subject to customary closing conditions and the successful acquisition of the GE Biopharma...

Free
Corporate Voice
Health Care
Sartorius AG
1y 21/10/2019 1 EN
BusinessWire

Nine-Month Figures for 2019: Sartorius Continues on Its Dynamic Growth Track

GÖTTINGEN, Germany--(BUSINESS WIRE)-- Sartorius, a leading international partner of biopharmaceutical research and the industry, performed dynamically in the third quarter as well, achieving double-digit growth rates in sales revenue, order intake and earnings in the first nine months. “Sartorius achieved significant double-digit growth rates in sales revenue and earnings for the first nine months of the year as well,” said Executive Board Chairman and CEO Dr. Joachim Kreuzburg. “In a challenging global economic environment, our Lab Products & Services Division showed a very robust third-qu...

Free
Corporate Voice
Health Care
Sartorius AG
1y 21/10/2019 1 EN
BusinessWire

Business Figures for the First Half of 2019: Sartorius Continues Double-digit Growth

GÖTTINGEN, Germany--(BUSINESS WIRE)-- Sartorius, a leading international partner of biopharmaceutical research and the industry, grew strongly in the first half of 2019, recording double-digit increases in sales revenue, order intake and earnings. Given these results and continued positive prospects for the Bioprocess Solutions Division for the second half, management has raised its full-year targets. “We are very pleased on the whole with business progress in the first half, though both divisions showed different growth dynamics,” said Executive Board Chairman and CEO Dr. Joachim Kreuzburg...

Free
Corporate Voice
Health Care
Sartorius AG
1y 19/07/2019 1 EN
BusinessWire

Sartorius Starts up Operations at Expanded Site in Puerto Rico

GÖTTINGEN, Germany & YAUCO, Puerto Rico--(BUSINESS WIRE)-- After investing more than 100 million U.S. dollars, Sartorius, a leading international partner of biopharmaceutical research and the industry, started up its expanded manufacturing operations in Yauco, Puerto Rico. The U.S. market is primarily supplied from this site, given that Sartorius has been growing strongly in this marketplace at above-average rates over the past several years. “Operationally and strategically, this expansion is an important investment for us. The considerabl...

Free
Corporate Voice
Health Care
Sartorius AG
1y 19/06/2019 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.22
Equity
Technology
ACCD , ACD ...
58d 23/11/2020 28 EN
EQUITS GmbH
Thomas J. Schiessle

Vorbereitungen für COVID-19-Vaccine bringt Orderschub von 60 % in Q3/20 - 4. Guidance-Anpassung für Gj. 2020

Überraschend kräftig entwickelte sich Q3/20; BPS (+26 % auf € 144,5 Mio.) wuchs anhaltend zweistellig; LPS (+44,1 % auf € 478,7 Mio.) beendete (mit Wiedereröffnung der akademischen Labore) die Schwächephase des H1/20 in allen Regionen. Der Ordereingang erreichte € 711,7 Mio. (+54,5% ggü. Vj; in CC: +60% - davon ca. 30%-Punkte COVID-19-bedingt). Der Q3/20-Konzern­umsatz stieg um +39,5 % ggü. Vj. (EMEA: +37,4%; Amerika: +38,7 %; Asia/Pacific:  +27,3 %) auf € 623,2 Mio. So gesehen könnte die herrschende Konzern-Mittelfristperspektive angehoben werden, sofern die anlaufende 2. Corona-Welle nicht ...

EUR 220.00
Equity
Health Care
SRT , SRT3 ...
92d 21/10/2020 4 DE
EQUITS GmbH
Thomas J. Schiessle

Preparations for COVID-19 vaccine brings order surge of 60 % in Q3/20 - 4th guidance adjustment for FY 2020

  Q3/20 developed surprisingly strongly; BPS (+26 % to € 144.5 m) continued to grow at double-digit rates; LPS (+44.1 % to € 478.7 m) ended the weak phase of H1/20 (with the reopening of academic laboratories) in all regions. Order intake reached € 711.7 m (+54.5 % vs. previous year; in CC: +60 % - thereof approx. 30 % points COVID-19 related). Consolidated sales in Q3/20 rose by +39.5 % year-on-year (EMEA: +37.4 %; America: +38.7 %; Asia/Pacific: +27.3 %) to € 623.2 m. Seen in this light, the prevailing medium-term outlook for the Group could be raised, provided that the ongoing second wave...

EUR 220.00
Equity
Health Care
SRT , SRT3 ...
92d 21/10/2020 4 EN
EQUITS GmbH
Thomas J. Schiessle

BIA Seperations Kauf verbessert Perspektiven

Für € 360 Mio. - davon für € 120 Mio. in Stedim Aktien – (+ Earn-out) wird der Aufreinigungsspezialist BIA Seperations (ca. 120 Mitarbeiter, Jahresumsatz: ca. € 25 Mio.) gekauft. Strategisch bedeutend: Das BIA-Produktportfolio ist im Markt anerkannt und erschließt künftige Medikamentenklassen (Advanced Therapies) für den global agierenden SRT-Konzern.

EUR 220.00
Equity
Health Care
SRT , 56S1
107d 06/10/2020 4 DE
EQUITS GmbH
Thomas J. Schiessle

Investoren sehr optimistisch – Konjunkturrisiken noch nicht ausgeräumt - Belastungen kommen noch

Eine Guidance-Anhebung wurde anlässlich des Q1/19-Interimberichtes – wie von uns erwartet - nicht vorgenommen. Laut Sartorius CEO Dr. Kreuzburg sei es zu früh eine Anhebung vorzunehmen, denn noch seien nicht die Belastungsfaktoren im 2019er-Planungsszenario zum Tragen gekommen.

EUR 160.00
Equity
Health Care
SRT , SRT3 ...
1y 25/04/2019 1 DE
Oddo BHF
Ahmed Ben Salem ...
  • Alfred Glaser
  • Bruno Cavalier
  • Delphine Brault
  • Fatma Agnès Hamdani
  • Oussema Denguir
  • Pierre Tegner

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 07/16/2018

...

Market Commentary
Industrial Goods & Services
Alstom - New , 002554 ...
2y 16/07/2018 26 EN
Oddo BHF
Ahmed Ben Salem ...
  • Alfred Glaser
  • Bruno Cavalier
  • Delphine Brault
  • Fatma Agnès Hamdani
  • Oussema Denguir
  • Pierre Tegner

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 16/07/2018

...

Market Commentary
Industrial Goods & Services
Alstom - New , 002554 ...
2y 16/07/2018 26 FR
Ford Equity Research

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

EUR 18.48
Quant
Health Care
Sartorius AG
4y 16/12/2016 2 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch